Basis: FMP quote market capitalization / four-quarter operating cash flow. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/OCF ratio is N/A as of 2026-10-06T15:47:34.958Z.
Calculation as of: 2026-10-06T15:47:34.958Z.
Quote observation: 2026-10-06T15:45:04.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 8656b7a9da6ad27e4e3bee00a1f051c5b9ad9ad1f17b43070ca9e23e03b297bf
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/OCF RATIO
N/A
Market Cap
$413.94M
Price/OCF Ratio
N/A
TTM Avg
6.66
3Y Avg
6.66
5Y Avg
6.66
Market Cap
$416.33M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$423.49M
Price/OCF Ratio
N/A
TTM Avg
42.94
3Y Avg
42.94
5Y Avg
42.94
Market Cap
$402.82M
Price/OCF Ratio
52.31
TTM Avg
165.92
3Y Avg
165.92
5Y Avg
153.23
Market Cap
$397.78M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$435.40M
Price/OCF Ratio
19.75
TTM Avg
23.17
3Y Avg
204.78
5Y Avg
202.88
| NAME | MARKET CAP | PRICE/OCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Neurogene Inc. (NGNE) | $416.01M | N/A | N/A | N/A | N/A |
| Atea Pharmaceuticals, Inc. (AVIR)vs › | $413.94M | N/A | 6.66 | 6.66 | 6.66 |
| Eikon Therapeutics, Inc. Common Stock (EIKN)vs › | $416.33M | N/A | N/A | N/A | N/A |
| Shoulder Innovations, Inc. (SI)vs › | $409.27M | N/A | N/A | N/A | N/A |
| Carlsmed, Inc. (CARL)vs › | $407.77M | N/A | N/A | N/A | N/A |
| Prothena Corporation plc (PRTA)vs › | $423.49M | N/A | 42.94 | 42.94 | 42.94 |
| Myriad Genetics, Inc. (MYGN)vs › | $402.82M | 52.31 | 165.92 | 165.92 | 153.23 |
| MapLight Therapeutics, Inc. (MPLT)vs › | $397.78M | N/A | N/A | N/A | N/A |
| NeoGenomics, Inc. (NEO)vs › | $435.40M | 19.75 | 23.17 | 204.78 | 202.88 |
| Kyverna Therapeutics, Inc. (KYTX)vs › | $388.79M | N/A | N/A | N/A | N/A |
P/OCF Ratio
N/A
P/FCF Ratio
N/A
P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
